About
iRhythm Technologies (NASDAQ:IRTC) has received a "Moderate Buy" consensus from 15 research firms, with an average 1-year target price of $205.71. Recent ratings include Goldman Sachs' "neutral" at $202, and Citigroup's "buy" at $242. Insider trading saw significant stock sales, and institutional investors have adjusted their positions. The stock opened at $181.35, with a 52-week range of $81.10 to $212.00.
Several healthcare and biotech stocks saw significant gains in after-hours trading on Thursday due to clinical updates, earnings results, and regulatory developments. Sensei Biotherapeutics surged 62.9%, Praxis Precision Medicines rose 24.8%, CooperCompanies climbed 13.0%, Vanda Pharmaceuticals gained 7.5%, Cue Biopharma increased 7.8%, and ResMed added 3.7%. Key drivers included positive clinical trial results, earnings reports, and regulatory decisions.
On December 4, Eastern Time, Hims & Hers Health options saw a total of 86385 contracts traded, with calls accounting for 70% and puts making up 29%.
Insulet Corp. (PODD) stock rose 2.72% to $315.92, outperforming competitors in a mixed trading session. The S&P 500 Index rose 0.11%, while the Dow Jones fell 0.07%. Insulet's stock snapped a three-day losing streak and closed 10.98% short of its 52-week high. Trading volume exceeded its 50-day average. Competitors Eli Lilly & Co. fell 1.85%, DexCom Inc. rose 0.62%, and Johnson & Johnson fell 1.39%.
IQVIA Holdings Inc. stock fell 1.02% to $224.92 on Thursday, underperforming compared to competitors like HCA Healthcare and Centene Corp. The stock is 4% below its 52-week high of $234.30. The S&P 500 rose 0.11%, while the Dow Jones fell 0.07%. The data was compiled on December 4, 2025, by MarketWatch.
